揭示与年龄相关的黄斑退化症中的他类药物和遗传学:科因布拉眼睛研究报告9
Patrícia Barreto1,2,3, Cláudia Farinha1,2,3,4,5, Rita Coimbra1,6
1Association for Innovation and Biomedical Research on Light and Image (AIBILI), Coimbra, Portugal.
Investigative ophthalmology & visual science
|June 27, 2024
概括
类药物可以防止与年龄相关的黄斑变性 (AMD) 的进展. 遗传风险会影响他类药物的效果,这表明遗传在AMD治疗反应中起着作用.
科学领域:
- 眼科医生 眼科 眼科
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 与年龄相关的黄斑变性 (AMD) 是导致视力丧失的主要原因.
- 遗传因素显著影响AMD风险和进展.
- 类药物是广泛使用的降胆固醇药物,具有潜在的抗炎作用.
研究的目的:
- 调查他类药物使用与与年龄相关的黄斑退化症 (AMD) 的进展之间的关联.
- 为了确定AMD的遗传风险是否会改变他类药物对AMD进展的影响.
- 探索他类药物治疗和AMD遗传倾向之间的潜在相互作用.
主要方法:
- 对来自科恩布拉眼睛研究的682名参与者的分析,随访时间为6.5年.
- 基于在研究访问之间开始服用他类药物的基础上对参与者的分类.
- 使用52种与AMD相关的变体计算AMD遗传风险得分 (GRSs).
- 使用卡普兰-梅尔曲线和扩展的考克斯模型来评估AMD进展风险和相互作用.
主要成果:
- 静止素摄入与AMD进展风险降低48%,独立于AMD遗传风险.
- 具有高遗传风险分数且不服用他类药物的人与服用他类药物但基因风险较低的人相比,患AMD进展的风险增加了四倍.
- 高遗传风险显著增加了非他类药物使用者的AMD进展风险.
结论:
- 达丁类药物的使用似乎可以防止与年龄相关的黄斑退行症的进展.
- 遗传因素在AMD治疗他类药物的反应中起作用.
- 需要进一步的研究来阐明他类药物,遗传学和AMD进展之间的相互作用.
更多相关视频
10:14Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
Published on: May 26, 2023
3.1K
06:16Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies
Published on: July 28, 2023
2.5K
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...